title: Therapeutic effects on atopic dermatitis by anti-RelA short interfering RNA combined with functional peptides Tat and AT1002.
abstract: Atopic dermatitis (AD) has high morbidity and poor prognosis because safe and effective treatments are scarce. Recently, short interfering RNA (siRNA) has shown promise as an effective treatment for targeting specific aberrantly expressed genes. However, naked siRNAs are too inefficient because of various enzymatic, membrane, and cellular barriers. We previously reported that a Tat analog acting as a cell-penetrating peptide, combined with AT1002, which reversibly increases paracellular transport of molecules across the epidermal barrier in epidermis-disrupted mice and enhances the skin permeation of water-soluble siRNA. In the present study, to develop a novel treatment for AD, we determined the intradermal permeation of siRNAs and the antiallergic effects of a siRNA that silences RelA, a member of the nuclear factor-κB family, using Tat and AT1002 peptides in an AD mouse model. We first showed that the Tat analog and AT1002 delivered siRNA into the skin of ICR mice and, upon topical application to the AD-induced ears of NC/Nga mice, changed zonula occludens protein 1 expression. In addition, the silencing effects on the mRNA of RelA in JAWS II cells transfected with siRNA oligonucleotides for mouse RelA, complexed with Tat, were as effective as a commercial vector. Furthermore, the ear thickness, clinical skin severity, topical cytokine levels, and serum IgE production in AD model mice treated with anti-RelA siRNA with Tat and AT1002 were improved.
authors.affiliation: Department of Pharmaceutical Science, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan.
authors.forename: Tamae
authors.initials: T
authors.lastname: Uchida
authors.forename: Takanori
authors.initials: T
authors.lastname: Kanazawa
authors.forename: Misako
authors.initials: M
authors.lastname: Kawai
authors.forename: Yuuki
authors.initials: Y
authors.lastname: Takashima
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Okada
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D016503:Drug Delivery Systems / Q000379:methods; D004359:Drug Therapy, Combination; D005260:Female; D015696:Gene Products, tat / Q000008:administration & dosage* / Q000235:genetics; D020868:Gene Silencing / Q000502:physiology; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009842:Oligopeptides / Q000008:administration & dosage* / Q000235:genetics; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000037:antagonists & inhibitors / Q000235:genetics; D012869:Skin Absorption / Q000235:genetics; D051996:Transcription Factor RelA / Q000008:administration & dosage* / Q000235:genetics
chemical_list: C530561:AT1002; D015696:Gene Products, tat; D009842:Oligopeptides; D034741:RNA, Small Interfering; C498144:Rela protein, mouse; D051996:Transcription Factor RelA